Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Belhaven Reports Positive Nasdepi Dose Study in Allergic Rhinitis Patients
Details : Nasdepi is a dry powder formulation of epinephrine being developed for intranasal administration to treat Type 1 allergic reactions including anaphylaxis.
Product Name : Nasdepi
Product Type : Hormone
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $11.0 million
Deal Type : Financing
Belhaven Raises $11M for Nasdepi(R), Nasal Breakthrough for Anaphylaxis
Details : The financing from the proceeds will support the development of Nasdepi (epinephrine). It is being evaluated for the treatment of Anaphylactic reactions due to severe allergies.
Product Name : Nasdepi
Product Type : Hormone
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $11.0 million
Deal Type : Financing
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Lovelace Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution in Canine Study
Details : Nasdepi (epinephrine) a small molecule, dry powder nasal formulation is currently being investigated for the treatment of patients with anaphylactic reactions due to severe allergies.
Product Name : Nasdepi
Product Type : Hormone
Upfront Cash : Inapplicable
September 07, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Lovelace Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable